Axa’s Allogene Therapeutics ALLO Stock Holding History

Axa’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-28,300	Closed	-$141K	–	1064
2023 Q2	$141K	Buy	+28,300	New	+$153K	﹤0.01%	1055
2023 Q1	–	Sell	-337,400	Closed	-$2.12M	–	1104
2022 Q4	$2.12M	Buy	+337,400	New	+$3.12M	0.01%	765
2019 Q4	–	Sell	-171,755	Closed	-$4.68M	–	1166
2019 Q3	$4.68M	Sell	171,755 -303	-0.2%	-$8.63K	0.02%	670
2019 Q2	$4.62M	Buy	172,058 +68,773	+67%	+$1.92M	0.02%	678
2019 Q1	$2.99M	Buy	+103,285	New	+$3M	0.01%	776

Other funds holding ALLO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Axa's ALLO Position: Q3 2023 in Review

Axa sold out of Allogene Therapeutics (ALLO) in Q3 2023, closing a stake of 28,300 shares — an estimated $141K sold.

Axa first reported a position in ALLO in Q1 2019 and held it in 5 quarters. The position peaked at $4.68M in Q3 2019. 154 funds tracked by Wall St. Rank hold ALLO as of Q3 2023.

Axa reported no remaining Allogene Therapeutics position as of Q3 2023 after selling out during the quarter.
Axa sold 28,300 Allogene Therapeutics shares in Q3 2023, an estimated $141K.
Axa first reported a position in Allogene Therapeutics in Q1 2019 and held it in 5 quarters.
Axa's Allogene Therapeutics position peaked at $4.68M in Q3 2019.
154 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2023.

Based on Axa's 13F filing for Q3 2023, filed 14 Nov 2023.